morphine sulphate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 7 Diseases   379 Trials   379 Trials   12426 News 


«12...1011121314151617181920...216217»
  • ||||||||||  morphine sulphate / Generic mfg.
    Journal:  Meperidine compared to morphine for rigors associated with monoclonal antibody-related infusion reactions. (Pubmed Central) -  Jun 17, 2024   
    Both meperidine and morphine effectively manage MAB-related rigors within minimal safety concerns. These findings suggest that morphine is a suitable alternative to meperidine for this indication, which may influence future formulary decision, provide alternatives for drug shortage, and optimize supportive care for patients undergoing MAB therapy.
  • ||||||||||  morphine sulphate / Generic mfg.
    Preclinical, Journal, IO biomarker:  20- Deoxyingenol attenuate morphine-induced hippocampus neurotoxicity and memory impairments in rats. (Pubmed Central) -  Jun 17, 2024   
    20-DOI attenuated morphine administration in rats with chronic disease caused spatial learning and memory dysfunction. These mechanistic effects could be partially related to 20-DOI protecting the CA1 region of rat hippocampal neurons from the morphine-induced oxidative stress, apoptosis, and autophagy through TFEB.
  • ||||||||||  morphine sulphate / Generic mfg.
    Journal:  Trajectories of opioid use before and after cancer diagnosis: A population-based cohort study. (Pubmed Central) -  Jun 16, 2024   
    There is considerable heterogeneity in opioid use before and after cancer diagnosis. Our findings suggest non-cancer factors drive a significant proportion of post-diagnosis opioid use, but use increased significantly from the month of cancer diagnosis and never returned to pre-diagnosis levels.
  • ||||||||||  morphine sulphate / Generic mfg.
    Observational data, Journal:  Analysis of opioid analgesics consumption in Africa: a longitudinal study from a 20-year continental perspective. (Pubmed Central) -  Jun 15, 2024   
    In the context of global doubling in opioid consumption, Africa has shown insufficient and stagnant opioid consumption during the last 20 years. These findings underscore the need for policy reform to facilitate safe and responsible opioid access in Africa, particularly for legitimate indications such as cancer pain and palliative care.
  • ||||||||||  morphine sulphate / Generic mfg., tramadol hydrochloride / Generic mfg.
    Review, Journal:  Opioid prescribing for cancer pain in Latin America: systematic review. (Pubmed Central) -  Jun 15, 2024   
    More rigorous research on CPM in LA is needed. Additionally, a comprehensive review of opioid prescription patterns, including non-cancer diagnoses, is necessary.
  • ||||||||||  Clinical, Journal, Surgery:  Opioid-free versus opioid-based anesthesia in major spine surgery: a prospective, randomized, controlled clinical trial. (Pubmed Central) -  Jun 13, 2024   
    All patients received intraoperative sevoflurane, propofol, rocuronium, ketamine, dexamethasone, ondansetron and postoperative paracetamol and patient-controlled analgesia device set to deliver intravenous morphine for 48 hours after surgery...OFA can be an alternative to OBA in patients undergoing multilevel spine fusion surgery. OFA reduces opioids consumption in the first 24 hours and PONV.
  • ||||||||||  morphine sulphate / Generic mfg.
    Journal, Metastases:  Narcotic Consumption Analysis among Severely Injured and Advanced Aged Trauma Patients. (Pubmed Central) -  Jun 13, 2024   
    MMPC effectively reduces opioid consumption in a severely injured patient population while simultaneously improving pain control. Advanced age trauma patients can require complex pain management solutions and future research to determine their needs is recommended.
  • ||||||||||  morphine sulphate / Generic mfg.
    Journal:  Utility of Continuous Paravertebral Block after Retroperitoneal Abdominal Aortic Aneurysm Repair. (Pubmed Central) -  Jun 12, 2024   
    Caregivers may require additional counseling and palliative medications for HM-specific EOL symptoms. Continuous paravertebral block provides better pain management with significantly decreased opioid requirements in the postoperative period compared to GA-alone for patients undergoing elective retroperitoneal AAA repair.
  • ||||||||||  celecoxib oral / Generic mfg.
    Journal:  Evaluation of Postoperative Efficacy and Safety of Celecoxib in Children Hospitalized After Adenotonsillectomy. (Pubmed Central) -  Jun 12, 2024   
    This is the first description of the unique DEX mechanism acting as a Nrf2 activator against morphine-mediated oxidative harm, raising the possibility that the substance may be used to prevent bone defects. Using celecoxib early after an adenotonsillectomy has reduced both opioid use and duration of hospital stay without increasing adverse effects or bleeding.
  • ||||||||||  morphine sulphate / Generic mfg.
    Journal:  Regimes of pain: The geopolitics of cancer palliation in Pakistan. (Pubmed Central) -  Jun 11, 2024   
    It shows further how unviably low price ceilings, purported to ensure a poor population's access to morphine, render it scarce on the official market. These mutually reinforcing regimes of control thus thwart their own purported objectives, consigning cancer patients to preventable, yet unpalliated, pain.
  • ||||||||||  morphine sulphate / Generic mfg.
    Retrospective data, Journal:  Liposomal Bupivacaine Analgesia in Deep Inferior Epigastric Perforator Flap Breast Reconstruction: A Retrospective Cohort Study. (Pubmed Central) -  Jun 10, 2024   
    Patients receiving LB and those receiving bupivacaine were compared to assess opioid utilization in morphine milligram equivalents (MMEs) and healthcare resource utilization during perioperative (2 weeks before surgery to 2 weeks after discharge) and 6-month postdischarge periods...The LB cohort was less likely to have all-cause inpatient readmission (odds ratio, 0.670 [95% CI, 0.452-0.993]; P = 0.046) and outpatient clinic/office visits (odds ratio, 0.885 [95% CI, 0.785-0.999]; P = 0.048) 3 months after discharge than the bupivacaine cohort; other all-cause healthcare resource utilization outcomes were not different. LB was associated with fewer perioperative MMEs and all-cause 3-month inpatient readmissions and outpatient clinic/office visits than bupivacaine in patients undergoing DIEP flap breast reconstruction.
  • ||||||||||  morphine sulphate / Generic mfg.
    Journal, Surgery:  Enhanced Recovery after Surgery Protocol Decreases Length of Stay and Postoperative Narcotic Use in Tissue Expander-based Breast Reconstruction. (Pubmed Central) -  Jun 10, 2024   
    Patients in the ERAS cohort were more likely to undergo prepectoral reconstruction (83.1% versus 4.5%, P < 0.001), be discharged by day 1 (96.5% versus 70.2%, P < 0.001) and consume lower inpatient milligram morphine equivalent (MME) median (79.8 versus 151.8, P < 0.001)...Additionally, prepectoral reconstruction significantly decreased MME (?=-30.9, P = 0.015) and was the sole predictor of seroma development (odds ratio = 5.2, P = 0.009). ERAS protocols significantly reduce opioid use and hospital stay after TEBR.
  • ||||||||||  Seizalam (midazolam intramuscular) / Pfizer
    Review, Journal:  What is the evidence for using intranasal medicine in the prehospital setting? A systematic review. (Pubmed Central) -  Jun 7, 2024   
    There are likely to be certain populations, for example pediatrics, that will benefit the most, although conclusions are limited by the quality of evidence currently available. We encourage additional research in this area, particularly with robust prospective double-blind RCTs.
  • ||||||||||  morphine sulphate / Generic mfg., ibuprofen / Generic mfg.
    Preclinical, Journal:  Pain-suppressed consumption of highly palatable liquid in rats. (Pubmed Central) -  Jun 7, 2024   
    Although standard analgesics attenuate CFA-suppressed drinking, nonspecific hyperphagic effects can confound the interpretation of results. Thus, consumption of a highly palatable liquid is not an optimal measure for candidate analgesic screening.
  • ||||||||||  morphine sulphate / Generic mfg.
    Journal:  Blocking potential metabolic sites on NAT to improve its safety profile while retaining the pharmacological profile. (Pubmed Central) -  Jun 6, 2024   
    Previously our group reported a novel lead compound, NAT, a mu-opioid receptor antagonist that potently antagonized the antinociception of morphine and showed significant blood-brain barrier permeability...Compound 12 showed retention of the basic pharmacological attributes of NAT while improving the withdrawal effects that were experienced in opioid-dependent mice. Further studies will be conducted to fully characterize compound 12 to examine whether it would serve as a new lead for opioid use disorder treatment and management.
  • ||||||||||  morphine sulphate / Generic mfg.
    Preclinical, Journal:  Low doses of acetaminophen produce antidepressive-like effects through the opioid system in mice. (Pubmed Central) -  Jun 6, 2024   
    Also, the response of the non-effective dose of acetaminophen (25?mg/kg) was potentiated by the non-effective dose of morphine (0.1?mg/kg) in the FST that was antagonized by naloxone...Our findings demonstrated that acetaminophen in lower doses but not high doses revealed an antidepressant-like activity without inducing tolerance and withdrawal syndromes. Moreover, the observed effect of acetaminophen may be via altering the opioid system, particularly hippocampal mu- and kappa-receptors.
  • ||||||||||  morphine sulphate / Generic mfg.
    Journal:  Evaluating the Risk Index for Serious Prescription Opioid-Induced Respiratory Depression or Overdose in Patients with Cancer. (Pubmed Central) -  Jun 5, 2024   
    For Group 1, the most common CIP-RIOSORD predictive factors were use of a long-acting opioid formulation (n?=?24, 29%) and daily oral morphine equivalent (OME) ?100 (n?=?20, 24%); for Group 2, predictive factors were use of an antidepressant (n?=?34, 44%) and a long-acting opioid formulation (n?=?27, 35%). Based on the CIP-RIOSORD, there is a 15% probability of experiencing a serious OIRD event or overdose within the next 6?months.